|
BR112012005594A2
(en)
|
|
cancer treatment
|
|
BRPI0911147A2
(en)
|
|
liver cancer drug
|
|
DK2121139T3
(en)
|
|
FORMULATIONS FOR CANCER TREATMENT
|
|
BRPI1006438A2
(en)
|
|
adjuvant cancer therapy
|
|
BRPI0920521A2
(en)
|
|
pharmaceutical combination
|
|
IT1394860B1
(en)
|
|
PHARMACEUTICAL COMPOUNDS
|
|
ATE526024T1
(en)
|
|
FLUVOXAMINE-AVOIDING PIRFENIDONE THERAPY
|
|
BRPI1011587A2
(en)
|
|
therapeutic compounds and compositions
|
|
DK3097925T3
(en)
|
|
PHARMACEUTICAL COMPOSITION
|
|
BRPI1004940A2
(en)
|
|
pharmaceutical composition
|
|
BR112012002797A2
(en)
|
|
prostate cancer treatment
|
|
BRPI1015939A2
(en)
|
|
pharmaceutical composition
|
|
BRPI1013618A2
(en)
|
|
substituted pyrimidines for cancer treatment
|
|
BR112013011659A2
(en)
|
|
cancer treatment methods
|
|
BRPI1010874A8
(en)
|
|
composition for prostate cancer treatment
|
|
BRPI1005433A2
(en)
|
|
transdermal pharmaceutical preparations
|
|
BRPI1007995A2
(en)
|
|
ortho-aminoamides for the treatment of cancer.
|
|
SMT201700056B
(en)
|
|
PHOSPHAPLATIN AND ITS RELATED USE FOR CANCER TREATMENT
|
|
BRPI0922884A2
(en)
|
|
cancer treatment compounds
|
|
BRPI0922653A2
(en)
|
|
pharmaceutical preparation
|
|
IL222958A0
(en)
|
|
Cancer treatment
|
|
BR112013008074A2
(en)
|
|
pharmaceutical combinations
|
|
DK2147122T3
(en)
|
|
ENZYMATIC CANCER TREATMENT
|
|
BRPI0922367A2
(en)
|
|
enzastaurin for cancer treatment
|
|
IT1393930B1
(en)
|
|
PHARMACEUTICAL COMPOUNDS
|